- Home
- JSPR vs ALGS Comparison
JSPR vs ALGS Comparison
Compare JSPR & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- ALGS
- Stock Information
- Founded
- JSPR 2018
- ALGS 2018
- Country
- JSPR United States
- ALGS United States
- Employees
- JSPR N/A
- ALGS N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- ALGS Health Care
- Exchange
- JSPR Nasdaq
- ALGS Nasdaq
- Market Cap
- JSPR 47.3M
- ALGS 53.0M
- IPO Year
- JSPR N/A
- ALGS 2020
- Fundamental
- Price
- JSPR $3.15
- ALGS $9.13
- Analyst Decision
- JSPR Buy
- ALGS Strong Buy
- Analyst Count
- JSPR 12
- ALGS 1
- Target Price
- JSPR $31.67
- ALGS $70.00
- AVG Volume (30 Days)
- JSPR 1.5M
- ALGS 85.7K
- Earning Date
- JSPR 08-12-2025
- ALGS 08-05-2025
- Dividend Yield
- JSPR N/A
- ALGS N/A
- EPS Growth
- JSPR N/A
- ALGS N/A
- EPS
- JSPR N/A
- ALGS N/A
- Revenue
- JSPR N/A
- ALGS $3,270,000.00
- Revenue This Year
- JSPR N/A
- ALGS N/A
- Revenue Next Year
- JSPR N/A
- ALGS $51.55
- P/E Ratio
- JSPR N/A
- ALGS N/A
- Revenue Growth
- JSPR N/A
- ALGS N/A
- 52 Week Low
- JSPR $2.27
- ALGS $3.76
- 52 Week High
- JSPR $26.05
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- JSPR 34.82
- ALGS 59.79
- Support Level
- JSPR $3.08
- ALGS $8.18
- Resistance Level
- JSPR $3.31
- ALGS $9.44
- Average True Range (ATR)
- JSPR 0.32
- ALGS 0.71
- MACD
- JSPR -0.04
- ALGS 0.01
- Stochastic Oscillator
- JSPR 34.11
- ALGS 65.95
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.